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Abstract
Background: It is difficult to predict survival in patients with idiopathic pulmonary fibrosis. Recently, several
proteins, such as surfactant protein (SP) and KL-6, have been reported to be useful biologic markers for prediction
of prognosis for interstitial pneumonias. It is not clear whether there is any relationship between expression of
these proteins in regenerative/hyperplastic alveolar epithelial cells and prognosis of idiopathic interstitial
pneumonias (IIPs).
Objectives: This study aimed to elucidate the clinical significance of the expression of such lung secretory proteins
as SP-A and KL-6 in lung tissues of patients with IIPs.
Methods: We retrospectively investigated the immunohistochemical expression of SP-A, KL-6, cytokeratin (CK), and
epithelial membrane antigen (EMA) in alveolar epithelial cells in lung tissues obtained from surgical lung biopsy in
43 patients with IIPs, and analyzed the correlation between expression of these markers and the prognosis of each
IIP patient. CK and EMA were used as general markers for epithelial cells.
Results: In patients with usual interstitial pneumonia (UIP), the ratio of SP-A positive epithelial cells to all alveolar
epithelial cells (SP-A positive ratio) in the collapsed and mural fibrosis areas varied, ranging from cases where
almost all alveolar epithelial cells expressed SP-A to cases where only a few did. On the other hand, in many
patients with nonspecific interstitial pneumonia (NSIP), many of the alveolar epithelial cells in the diseased areas
expressed SP-A. The SP-A positive ratio was significantly lower in patients who died from progression of UIP than
in patients with UIP who remained stable or deteriorated but did not die. In NSIP patients, a similar tendency was
noted between the SP-A positive ratio and prognosis.
Conclusions: The results suggest that the paucity of immunohistochemical SP-A expression in alveolar epithelial
cells in diseased areas (i.e. regenerative/hyperplastic alveolar epithelial cells) may predict a worse prognosis for
patients with IIPs, especially patients with UIP. A prospective study is needed to confirm these results.
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Idiopathic pulmonary fibrosis (IPF) is a form of idio-
pathic interstitial pneumonia (IIP) characterized by pro-
gressive lung fibrosis and a poor prognosis. It is difficult
to predict survival in patients with IPF. Longer survival
has been associated with younger age, female gender, a
shorter symptomatic period prior to diagnosis, less dys-
pnea, preserved pulmonary function, the extent of
ground-glass and reticular opacities on high-resolution
CT scans, lymphocytosis in broncho-alveolar lavage
fluid (BALF), less fibroblastic foci in the histological sec-
tions, and a better response to treatment [1-7].
Recently, several lung secretory proteins, such as sur-
factant protein (SP) and KL-6, were reported to be use-
ful biologic markers for predicting prognosis of
interstitial pneumonia (IP) [8-14]. KL-6 is expressed on
epithelial cells, being a mucin-like glycoprotein. Studies
revealed that patients with IPF and an elevated serum
level of SP-A, SP-D, or KL-6 had a poor prognosis
[10-14]. On the other hand, expression of these proteins
in regenerative/hyperplastic alveolar epithelium in IIP
has been reported to differ among subtypes of IIP [15].
However, it is not clear whether there is any relation-
ship between expression of lung secretory proteins in
regenerative/hyperplastic alveolar epithelium and prog-
nosis in the subtypes of IIP.
T h i ss t u d ya i m e dt od e t e r m i n eap o s s i b l er e l a t i o n s h i p
between patient’s prognosis and immunohistochemical
expression of SP-A, KL-6, cytokeratin (CK) and epithe-
lial membrane antigen (EMA) in regenerative/hyperplas-
tic alveolar epithelial cells of IIPs. We retrospectively
examined immunohistochemical expression of SP-A,
KL-6, cytokeratin (CK) and epithelial membrane antigen
(EMA) in surgical lung biopsy samples obtained from 43
patients with IIP. We used CK and EMA as general
markers for epithelial cells.
Methods
Subjects
We studied 43 patients with IIPs who underwent surgi-
cal lung biopsy between 1995 and 2006 and were fol-
lowed for at least three years after biopsy in the
National Hospital Organization group hospitals in
Kyushu District (Omuta, Fukuoka Higashi, Minami
Kyushu, and Kumamoto Saishunso Hospitals), and Kur-
ume University Hospital. Mean follow-up time is men-
tioned in Table 1. The study population included 8
patients who died within two years after biopsy. Two
independent pathologists reviewed the histological sec-
tions. The final IIP diagnosis incorporated histological,
radiological and clinical features, and was based on the
American Thoracic Society/European Respiratory
Society international multidisciplinary consensus classifi-
cation of the idiopathic interstitial pneumonias [16]. The
study population consisted of 19 usual interstitial pneu-
monia (UIP) patients (13 male and 6 female, 42 to 78
years), 17 nonspecific interstitial pneumonia (NSIP)
patients (11 male and 6 female, 42 to 70 years), one
cryptogenic organizing pneumonia (COP) patient
(female, 64 years), one desquamative interstitial pneu-
monia (DIP) patient (male, 59 years), one respiratory
bronchiolitis-interstitial lung disease (RB-ILD) patient
(male, 64 years), and four unclassifiable IP patients
(three male and one female, 56 to 66 years). Table 1
summarizes the salient clinical features of the patients
with UIP and NSIP, the two main subtypes of IIP in this
study. Mean smoking indices were 20.4, 22.1, and 22.1
pack-years in UIP, NSIP, and unclassifiable IP patients,
respectively. Smoking indices for DIP and RB-ILD
patients were 90 and 44 pack-years, respectively. A COP
patient was a non-smoker. No drugs were prescribed to
15 of the 19 UIP patients following biopsy. The remain-
ing four patients were treated with 0.5 - 1.0 mg/kg/day
of oral prednisolone following biopsy, which was gradu-
ally tapered. Following biopsy, 11 of the 17 NSIP
patients were treated with the same dosing of oral pre-
dnisolone. Two NSIP patients were treated with 0.5 mg/
kg/day of oral prednisolone and 1 mg/kg/day of oral
cyclophosphamide, and one NSIP patient received 100
mg/day of oral cyclosporine A. The remaining three
patients with NISP were not prescribed any drugs fol-
lowing lung biopsy. All DIP and COP patients were
treated with 1 and 0.5 mg/kg/day of oral prednisolone,
respectively, which was gradually tapered. Two patients
with unclassifiable IP were treated with 10 and 15 mg/
day of oral prednisolone, respectively, while no drugs
were prescribed to the remaining two unclassifiable IP
patients. The institutional ethical review boards of each
hospital approved this study. Subjects who were alive at
the time of sample collection gave written informed
consent to participate in the study.
Immunohistochemistry
Immunohistochemical staining was performed using the
labeled streptavidin biotin method (DAKO LSAB2 kit,
Table 1 Salient clinical features of patients with IIPs
IIPs UIP NSIP
No. of patients 43 19 17
Age, years* 61.6 ± 8.8 63.6 ± 10.0 59.0 ± 8.6
Sex, M/F 29/14 13/6 11/6
%VC before biopsy (%)* 82.5 ± 16.6 77.8 ± 17.2 84.8 ± 17.5
PaO2 before biopsy (torr)* 77.5 ± 9.9 80.7 ± 9.8 73.7 ± 9.8
Duration of illness before biopsy
(months)*
17.4 ± 21.3 13.8 ± 13.7 21.8 ± 25.1
Duration of follow up after
biopsy (months)*
41.8 ± 29.6 27.3 ± 21.7 46.8 ± 21.6
*Data are presented as mean ± SD.
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Page 2 of 9DAKO Japan, Kyoto). The antibodies used in this study
were mouse anti-surfactant apoprotein A (SP-A) mono-
clonal antibody, mouse anti-cytokeratin, MNF116 (CK)
monoclonal antibody, which recognizes cytokeratin 5, 6,
8, 17, and 19, and mouse anti-epithelial membrane anti-
gen (EMA) monoclonal antibody (all obtained from
DAKO Japan, Kyoto), as well as mouse anti-KL-6 mono-
clonal antibody (Eizai Co., Ltd., Tokyo). Endogenous
peroxidase activity was blocked by treating sections with
3% H2O2 for 10 min. The sections were then sequen-
tially treated with primary antibody (anti-SP-A, CK,
EMA, or KL-6 antibody, all diluted 100×), biotinylated
goat anti-mouse immunoglobulin antibody, and strepta-
vidin-horseradish peroxidase. After these treatments,
peroxidase activity was revealed by incubating the sec-
tions in 0.05% 3,3’-diaminobenzidine containing 0.001%
H2O2. Sections in which the primary antibody was
replaced with normal mouse IgG served as a negative
control.
Quantification of the ratio of SP-A positive epithelial cells
to all alveolar epithelial cells in diseased areas (SP-A
positive ratio)
The 3-micrometer thick sections stained with immuno-
peroxidase were examined with a microscope to which a
light video camera was attached (Nikon Co., Tokyo).
Images were projected on a color monitor. The total
magnification was 140 (magnification of microscopic
objective lens × 10 and that of the light video camera ×
14). Next, images were printed out on A4-sized paper.
Numbers of all alveolar epithelial cells in diseased areas,
which were considered to be regenerative/hyperplastic
ones, and SP-A positive epithelial cells in the same areas
were counted manually on the image printouts. This
allowed the calculation of the ratio of SP-A positive
epithelial cells to all alveolar epithelial cells in diseased
areas (i.e. regenerative/hyperplastic alveolar epithelial
cells). For samples from patients with UIP, we examined
areas of collapsed and mural fibrosis. Areas of end-stage
lung (honeycomb) and normal lung were not included
in the counting.
To determine the number of fields required to esti-
mate the mean for each section, the number of SP-A
positive epithelial cells was divided by the number of all
alveolar epithelial cells in the diseased areas for five ran-
domly selected fields in sections from 10 patients. Esti-
mation of the SEM (standard error of the mean) within
90% confidence limits required a minimum of six fields
[17]. Formal scoring was then performed in seven ran-
domly selected fields in one section for each patient.
Using 50 randomly selected fields (10 fields from 5
patients), we assessed the variability in the number of
SP-A positive epithelial cells and all alveolar epithelial
cells in diseased areas counted by the two observers.
The coefficients of variation were 2.1% for the number
of SP-A positive epithelial cells and 3.5% for the number
of all alveolar epithelial cells in diseased areas.
Immunohistochemical staining of KL-6, CK and EMA
was analyzed only qualitatively.
Assessment of fibroblastic foci (FF), established fibrosis,
interstitial inflammation, and alveolar surface area in UIP
We assessed the number of FF in UIP tissue samples
according to the modified method reported by Nichol-
son et al [18]. The 3-micrometer thick sections stained
with alcian blue - periodic acid Schiff (AB-PAS) were
viewed at low-power magnification (×40), and the num-
ber of FF was counted within each low-power magnifi-
cation field by two observers. This was undertaken in
three separate areas where activity appeared to be most
marked within each biopsy, and the average FF number
within a lower-power magnification field was obtained
(FF score). In cases with biopsies from two different
sites, an average score was taken. The coefficient of var-
iation was 2.0%.
A semiquantitative assessment was undertaken for
each individual biopsy using a scale of 0-3 to describe
the extent of established fibrosis and interstitial inflam-
mation by the two observers. For established fibrosis, a
score of 0 represented no fibrosis, and a score of 3
represented end-stage or honeycomb lung. For intersti-
tial inflammation, a score of 0 represented no inflamma-
tion, and a score of 3 represented the degree of
infiltration expected in a pattern of lymphocytic intersti-
tial pneumonia. Kappa coefficients of agreement were
0.82 for established fibrosis, and 0.46 for interstitial
inflammation. Alveolar surface area was assessed quanti-
tatively by the two observers as the ratio of alveolar sur-
face area to the counted field using the point-counting
technique. The coefficient of variation was 2.9%.
Assessment of immunohistochemical MIB1 (Ki-67) nuclear
expression in the alveolar epithelial cells in the diseased
areas
To elucidate the proliferation activity of alveolar epithe-
lial cells, we examined immunohistochemical MIB1 (Ki-
67) nuclear expression in 6 UIP cases for which the SP-
A positive ratios were 75.3, 64.3, 48.4, 7.7, 7.7, and 7.7%,
and in 3 NSIP cases for which the SP-A positive ratios
were 95.6, 80.5, and 88.6%, using the same immunohis-
tochemical method described above and mouse anti-
MIB1 (Ki-67) monoclonal antibody (DAKO Japan,
Kyoto) diluted 100 ×. The number of alveolar epithelial
cells staining positive for MIB1 (Ki-67) in the diseased
area was expressed as a percentage of the total alveolar
epithelial cells in the same areas. These were counted
up to 600 cells using the same method as was used to
calculate the SP-A positive ratio.
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We classified the prognosis of the IIPs into three categories:
deteriorated, stable, and improved. A deteriorated prog-
nosis was defined as follows, (1) the patient’sd e a t hr e s u l t e d
from progression of the IIP, (2) the patient was started on
long-term oxygen therapy, or (3) within the period of a
year the patient’s vital capacity decreased by 0.3 liters or
10%. An improved prognosis was defined as an increase in
vital capacity by 0.3 liters/year or 10%/year. A stable prog-
nosis corresponded to a disease course that could not be
classified as either deteriorated or improved. The definition
of acute exacerbation of IIP is based on the criteria
reported by Noth and Martinez [19]. We assessed the out-
come regarding the prognosis of all cases of IIP in March,
2009. The mean time following biopsy in which the assess-
ment was done was 3.8, 3.0, 3.7, and 3.8 years in all cases,
UIP, NSIP, and unclassifiable IP cases, respectively. The
outcome was assessed 7.4, 12, and 4.9 years following
biopsy in patients with COP, DIP, and RB-ILD, respectively.
Statistical analysis
Data were expressed as mean ± SD (standard deviation).
One-way ANOVA (analysis of variance) and Fisher’s
PLSD (protected least significant difference) were used to
determine the correlation between the SP-A positive ratio
and the prognosis of IIPs in addition to that between the
prognosis of UIP and the extent of interstitial inflamma-
tion or established fibrosis, or the FF score. We evaluated
the correlations between the SP-A positive ratio and per-
cent of vital capacity (%VC), duration of illness, extent of
established fibrosis, or alveolar surface area, using the
Pearson’s correlation coefficient. Using the unpaired t-test,
we analyzed differences in the SP-A positive ratio between
the patients with UIP and NSIP as well as differences
between treated and untreated UIP or NSIP patients.
Time differences in the follow up period after lung biopsy
between patients who died from progression of UIP and
stable patients were also analyzed by unpaired t-test. P <
0.05 was considered statistically significant.
Results
Expression of SP-A, KL-6, CK, and EMA in alveolar
epithelial cells in diseased areas
In patients with IIP, the ratio of SP-A positive epithelial
cells to all alveolar epithelial cells in diseased areas (i.e.
regenerative/hyperplastic alveolar epithelial cells) varied,
ranging from cases where almost all alveolar epithelial
cells expressed SP-A to cases where only a few did
(Figure 1). Expression patterns of SP-A in the epithelial
cells of UIP patients were similar to those of IIP patients.
(Figurs 2, 3A and 3B). Many alveolar epithelial cells in
the diseased areas expressed SP-A in NSIP patients
(Figure 4A), except for three NSIP patients in whom only
a few epithelial cells expressed SP-A (Figure 5). The SP-
A positive ratio was significantly lower in UIP (34.0 ±
28.1%) than in NSIP (69.1 ± 24.2%) (p < 0.0005).
Almost all alveolar epithelial cells in diseased areas
revealed CK immunoreactivity (Figures 3C and 4B) in
patients from all IIP groups, with the exception of three
patients (one patient each with NSIP, RB-ILD, and unclassi-
fiable IP) in whom only a few epithelial cells expressed CK.
In all IIP patients, almost all alveolar epithelial cells in
diseased areas stained positive for KL-6 (Figures. 3D and
4C) and EMA (Figures. 3E and 4D).
Prognosis of IIPs
Table 2 lists the prognosis of all IIP patients as well as
the prognosis for patients of each subtype (UIP, NSIP,
COP, DIP, RB-ILD, and unclassifiable IP).
Correlation between immunohistochemical expression of
SP-A, KL-6, CK and EMA in alveolar epithelial cells in
diseased areas and prognosis of IIPs
In patients with IIPs as a whole and in those with UIP,
the SP-A positive ratio was significantly lower in those
who died from progression of IP than in patients with
another prognosis (stable, improved and deteriorated but
alive) (Figs. 1 and 2). The SP-A positive ratio for 10 out
Figure 1 Relation of SP-A expression in regenerative/
hyperplastic alveolar epithelial cells to prognosis of IIPs in all
patients. SP-A positive ratio = number of SP-A positive epithelial
cells/total number of alveolar epithelial cells in studied areas × 100.
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less than 0.4. On the other hand, the SP-A positive ratio
for only one out of 8 UIP patients who showed another
prognosis was less than 0.4. In NSIP patients, a similar
trend was noted for the SP-A positive ratio in alveolar
epithelial cells in diseased areas and prognosis (p =
0.0842) (Figure 5). In IIP patients, no specific relationship
was apparent between immunohistochemical expression
of CK, KL-6, or EMA in the alveolar epithelial cells in
diseased areas and prognosis of IIPs.
Correlation between the FF score, extent of established
fibrosis, or interstitial inflammation and UIP prognosis
No significant relation was seen between the FF score
and each prognosis of UIP, that is, stable, deteriorated
but alive, and deteriorated and died (p = 0.1137), though
the FF score was significantly higher in patients who
showed deteriorated clinical course than in those with
stable clinical course (p = 0.0372, Figure 6). No specific
correlation was apparent between UIP prognosis and
either the extent of established fibrosis (p = 0.4287), or
interstitial inflammation (p = 0.1554).
Correlation between the SP-A positive ratio and FF score,
the extent of established fibrosis, or alveolar surface area
in UIP
There was a significant inverse correlation between
the SP-A positive ratio and the FF score (r = -0.467,
Figure 2 Relation of SP-A expression in regenerative/
hyperplastic alveolar epithelial cells to prognosis of UIP
patients. SP-A positive ratio = number of SP-A positive epithelial
cells/total number of alveolar epithelial cells in studied areas × 100.
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Figure 3 A-E Immunohistochemical staining of SP-A (A, B), CK (C), KL-6 (D), and EMA (E) in lung tissue obtained from UIP patients.
Figs. B-E show tissue obtained from the same patient. While many regenerative/hyperplastic alveolar epithelial cells expressed SP-A in a lung
tissue from a UIP patient (A), SP-A expression is observed in only a few regenerative/hyperplastic alveolar epithelial cells and in intraalveolar
macrophages in lung tissue from another patient (B). Almost all regenerative/hyperplastic alveolar epithelial cells expressed CK, KL-6, and EMA (C,
D,E). (Immunoperoxidase and hematoxylin, × 140).
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the SP-A positive ratio and either the extent of estab-
lished fibrosis (r = 0.101, p = 0.7041) or alveolar surface
area (r = -0.217, p = 0.5886).
Immunohistochemical MIB (Ki-67) nuclear expression in
the alveolar epithelial cells in diseased areas
Cells staining positive for MIB (Ki-67) were observed in 1.8,
3.7, 1.3, 1.9, 1.7, and 2.7% of all alveolar epithelial cells in
collapsed and mural fibrosis areas in UIP cases for which
the SP-A positive ratios were 75.3, 64.3, 48.4, 7.7, 7.7, and
7.7%, respectively. In NSIP cases for which the SP-A posi-
tive ratios were 95.6, 88.6, and 80.5%, cells staining positive
for MIB (Ki-67) were observed in 4.5, 7.6, and 5.8%, respec-
tively, of all alveolar epithelial cells in diseased areas.
SP-A positive ratio between treated and untreated UIP or
NSIP patients
The mean SP-A positive ratio of treated and untreated
UIP patients was 41.8% and 33.9%, respectively, and that
of treated and untreated NSIP patients was 71.4% and
61.7%, respectively. There was no statistically significant
difference in the SP-A positive ratio between treated
and untreated UIP (p = 0.6474) or NSIP patients (p =
0.4987).
Follow-up periods after lung biopsy in UIP patients who
died from progression of UIP, and who showed stable
clinical course
The five UIP patients with a stable clinical course after
lung biopsy were followed for a significantly longer period
(39.0 ± 15.6 months) than the 11 patients who died from
progression of UIP (17.2 ± 12.2 months) (p = 0.0071).
Correlation between the SP-A positive ratio and illness
duration prior to lung biopsy, and %VC at the time of
lung biopsy
Thirty-three patients visited hospitals because of subjec-
tive symptoms. The mean SP-A positive ratio for this
patient group was 53.7 ± 29.3. There was no correlation
$ $ %
& ᨀ
Figure 4 A-D Immunohistochemical staining of SP-A (A,), CK (B), KL-6 (C), and EMA (D) in lung tissue obtained from an NSIP patient.
Many regenerative/hyperplastic alveolar epithelial cells expressed SP-A, CK, KL-6, and EMA in lung tissue from an NSIP patient.
(Immunoperoxidase and hematoxylin, × 140).
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lung biopsy for any of the patients (r = 0.023, p =
0.8860), or in those who visited hospitals because of
subjective symptoms (r = 0.101, p = 0.5853). Similarly,
no correlation was found between the SP-A positive
ratio and duration of illness before lung biopsy in all
patients (r = -0.065, p = 0.6886), or in those who visited
hospitals because of subjective symptoms (r = -0.044,
p = 0.8117).
Discussion
This is the first report to describe the relationship
between immunohistochemical SP-A expression in
alveolar epithelial cells in diseased areas (i.e.,
regenerative/hyperplastic alveolar epithelial cells) and
prognosis of IIPs, especially UIP. From the present
study, a paucity of immunohistochemical SP-A expres-
sion in regenerative/hyperplastic alveolar epithelial cells
is considered to predict worse prognosis of IIPs, espe-
cially UIP. The presence of significant inverse correla-
tion between the SP-A positive ratio and the FF score,
which has already been reported to predict the prog-
nosis of UIP [18], also supports this result. It is possible
that UIP patients whose regenerative/hyperplastic alveo-
lar epithelial cells did not express SP-A had a long-
standing illness preceding lung biopsy, and therefore
showed poor prognosis. However, there was no correla-
tion between the SP-A positive ratio and the duration of
illness or the %VC at the time of lung biopsy. Therefore,
we consider this possibility highly unlikely.
We anticipate that more UIP patients might die if they
are observed for a longer period. Though we conducted
this study retrospectively, UIP patients with stable clini-
cal courses were observed for significantly longer peri-
ods compared to those who died from UIP progression.
Therefore, it is unlikely that differences in the follow-up
period after lung biopsy affected the assessment of
prognosis.
Regenerative/hyperplastic alveolar epithelial cells that
did not express SP-A expressed other markers such as
CK, KL-6, and EMA. Among the cells that did not
express SP-A, a few regenerative/hyperplastic alveolar
epithelial cells expressing SP-A were intermingled. In
addition, type II alveolar epithelial cells seen in the nor-
mal alveolar tissue among the diseased lung tissue were
stained positively with SP-A. From these findings, we
think that the lack of SP-A expression was not an arti-
fact, and did not result from inappropriate fixation or
staining techniques.
In a preliminary study, we found that only a few
epithelial cells lining the honeycomb expressed SP-A,
irrespective of SP-A positive ratio of collapsed and
mural fibrosis areas in UIP. Other investigator also
reported the paucity of SP-A positive epithelial cells in
the honeycomb lesion [15]. Counting results are thus
highly influenced by the honeycomb area, and might
only reflect the occupied area of honeycomb lung, pro-
vided the area is included in the counting. Therefore,
Figure 5 Relation of SP-A expression in regenerative/
hyperplastic alveolar epithelial cells to prognosis of NSIP
patients. SP-A positive ratio = number of SP-A positive epithelial
cells/total number of alveolar epithelial cells in studied areas × 100.
Table 2 Prognosis of IIP patients
IIPs UIP NSIP COP DIP RB-ILD unclassifiable
Number of patients 43 19 17 1 1 1 4
Prognosis (number of patients)
deteriorated, died (died of acute exacerbation) 13 (12) 11 (10) 1 (1) 0 0 0 1 (1)
deteriorated, alive 6 3 2 0 0 0 1
stable 18 5 9 0 1 1 2
improved 6 0 5 1 0 0 0
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On the other hand, we did not also include normal area
in the counting, because the aim of the present study
was to investigate the expression of epithelial cell mar-
kers such as SP-A in regenerative/hyperplastic alveolar
epithelial cells of IIPs.
We examined how corticosteroid or immunosuppres-
sive therapy might affect expression of SP-A in alveolar
epithelial cells and found no statistically significant dif-
ferences in the SP-A positive ratios between treated and
untreated UIP or NSIP patients. Therefore, it is unlikely
that corticosteroid or immunosuppressive therapy
affected the correlation between the SP-A positive ratio
and the prognosis for UIP or NSIP patients, although
the patient population was small.
The reason a paucity of immunohistochemical SP-A
expression related to a worse prognosis in UIP patients
is unclear. SP-A is reported to play an important role in
the regulation of pulmonary inflammation [20-23].
Therefore, a lack of SP-A expression may induce an
exaggerated inflammatory reaction, such as an overpro-
duction of inflammatory cytokines to a given stimulus (a
viral infection, for example) and cause deterioration of
UIP. We do not know whether the regenerative/hyper-
plastic alveolar epithelial cells that lacked SP-A
expressed other surfactant apoproteins. If expression of
surfactant as a whole is poor in lungs of UIP patients,
the patients may suffer from a condition similar to
respiratory distress syndrome, for which the clinical
course is poor. The type II alveolar epithelial cell is the
major source of pulmonary surfactant, which functions
to reduce surface tension forces and the tendency of the
alveolar spaces to collapse. The reduction in surfactant
production by the type II cells in IPF [23-26] may pro-
mote atelectasis, resulting in the apposition and fibrotic
fusion of the denuded alveolar basement membranes
[27]. Alveolar epithelial markers, which reflect the capa-
city of the type II cells to respond appropriately to
injury, may predict clinical outcome of IPF.
McCormac et al. reported that IPF patients whose
BALF showed a low SP-A to total phospholipid ratio
experienced a worse prognosis [8,9]. Though we did not
measure serum or BALF SP-A concentrations in the
present study, our current results are consistent with
those of McCormac et al. Previous studies report that
IPF patients with high SP-A serum concentrations had
poor prognoses [10-12]. Takahashi et al. reported a time
lag between SP-A or D concentrations in the serum and
BALF in radiation-induced lung injury in rats [14]. This
may explain the different results reported for the corre-
lation between SP-A or D concentrations in the serum
or BALF and IPF prognosis.
The SP-A positive ratio in lung tissue of UIP patients
was significantly lower than that for NSIP patients. This
difference may reflect the different courses of disease
progression in these two types of interstitial pneumonia.
Another possible explanation is that characteristics or
function of regenerative epithelial cells differ between
UIP and NSIP. Though the number of samples studied
was small, the different percentages of alveolar epithelial
cells staining positive for MIB1 (Ki-67) between UIP
and NSIP patients noted in the present study may sup-
port this idea. In an investigation of the phenotypes of
regenerative epithelial cells in UIP and NSIP patients,
Hinata et al. proposed different origins of regenerative
epithelial cells in the two interstitial pneumonias [15].
Figure 6 Correlation between FF score and UIP prognosis.T h e
FF score indicates the number of fibroblastic foci within a lower-
power magnification field.
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Figure 7 Correlation between the SP-A positive ratio and FF
score in UIP patients. SP-A positive ratio = number of SP-A
positive epithelial cells/total number of alveolar epithelial cells in
studied areas × 100. FF scores indicate the number of fibroblastic
foci within a lower-power magnification field.
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approach is necessary to confirm the relationship
between immunohistochemical expression of surfactant
protein to the patient prognosis in IIPs, particularly UIP.
Conclusions
The results of the present study suggest that the paucity
of immunohistochemical SP-A expression in regenera-
tive/hyperplastic alveolar epithelial cells may predict a
worse prognosis for patients with IIPs, especially those
with UIP. A prospective study is needed to confirm
these results.
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